RecruitingPhase 4NCT04707261

Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

A Prospective, Randomized, Double-blind, Multicenter Study on the Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

Sponsor

Xiangtan Central Hospital

Enrollment

1,990 participants

Start Date

Aug 6, 2021

Study Type

INTERVENTIONAL

Conditions

Heart Failure Anemia

Summary

The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria3

Male or female between the ages of 18 and 100 years.
Elevated NT-proBNP or BNP levels on admission.
Ejection fraction of 50% or less, and New York Heart Association (NYHA) class II, III, or IV symptoms.

Exclusion Criteria3

Treatment with SGLT2-i during the past 3 months of admission,or previous intolerance of an SGLT2 inhibitor.
Severe (eGFR \<30 mL/min/1.73 m\^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization.
Pregnant or breast feeding female patients.